An effective AKT inhibitor-PARP inhibitor combination therapy for recurrent ovarian cancer

BACKGROUND: Although the use of PARP inhibitor has received considerable amount of attention in ovarian cancer, PARP inhibitor resistance still emerges with disease progression. PI3K/AKT pathway inhibitors have been proposed to synergize with PARP inhibition to slow tumor growth, but the exact molec...

Descripción completa

Detalles Bibliográficos
Autores principales: Xu, Jing, Gao, Yi, Luan, Xiaotian, Li, Ke, Wang, Jing, Dai, Yilin, Kang, Mingyi, Lu, Chong, Zhang, Minhua, Lu, Chris X., Kang, Yu, Xu, Congjian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2022
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9054880/
https://www.ncbi.nlm.nih.gov/pubmed/35419627
http://dx.doi.org/10.1007/s00280-022-04403-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9054880/
https://www.ncbi.nlm.nih.gov/pubmed/35419627
http://dx.doi.org/10.1007/s00280-022-04403-9

Ejemplares similares